Shots:
Characterized by discomfort or pain in the chest, Angina develops when the heart does not receive adequate oxygen-rich blood
PharmaShots' Disease of the Month report aims to familiarize the general population with conditions impacting communities worldwide. The report outlines disease characteristics, types, symptoms, diagnosis, treatments, epidemiology, market size, clinical trial analysis, patient advocacy groups (PAGs),…
Shots:
Characterized by the thickening or hardening of arteries due to plaque buildup, atherosclerosis leads to complications like heart attack or stroke
PharmaShots' Disease of the Month report aims to familiarize the general population with conditions impacting communities worldwide. The report outlines disease characteristics, types, symptoms, diagnosis, treatments, epidemiology, market size, clinical trial analysis, patient…
Active Ingredient: rivaroxaban
Strength: 2.5 mg, 10 mg, 15 mg, and 20 mg
Dosage Form: Tablets
Mechanism of Action: Factor Xa inhibitors
First Approval: US (1 Jul 2011), EU (30 Sep 2008)
Revenue Analysis of Xarelto1
Xarelto has been an important driver of the revenue generated from the cardiovascular portfolio of Janssen. The blood thinner showed an increase of 4%…
Shots:
Dr. Mason spoke about the key findings from their in vitro study demonstrating EPA + statins effects in reduced lipid oxidation, which were presented at the ACC 2022
He also spoke about the study design of the REDUCE-IT trial and its importance in the approval of its candidate in metabolic and cardiovascular diseases
The interview summarizes…
Active Ingredients: Apixaban
Strength: 2.5 mg and 5 mg
Dosage Form: Tablet
Mechanism of Action: Factor Xa inhibitors
First Approval: US (Dec 28, 2012), EU (May 18, 2011)
Revenue1
Eliquis is a leading novel oral anticoagulant of BMS. The revenue for BMS continued to grow due to Eliquis and other recently launched new products. BMS and Pfizer jointly develop and…

